Dr. Bose on Novel Agents Under Investigation in Myelofibrosis

Prithviraj Bose, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel agents under investigation in myelofibrosis.

Novel agents are being studied in combination with ruxolitinib (Jakafi) and as single agents after JAK inhibitor failure, says Bose. CPI-0610, which is a bromodomain inhibitor, and navitoclax, which is a BCL-2/BCXL antagonist, have shown the most potential in combination with ruxolitinib.

Imetelstat, which is being studied as a single agent post-ruxolitinib, has shown evidence of a survival advantage. Because the drug wasn’t compared with an active agent, it's difficult to determine whether the agent has a real survival advantage, says Bose. However, in comparison to historical controls, it looks like it does.

PRM-151, is an anti-fibrotic drug that’s under investigation. The field also has preliminary data with the LSD1 inhibitor bomedemstat. All of these agents are active, and more data regarding these drugs are expected to be presented during the 2020 European Hematology Association Virtual Congress, concludes Bose.